Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study
2020
Abstract
The aim of our study was to prospectively monitor and analyze lipid metabolism abnormalities in de novo CML patients treated with NILO at the start and during the first year of tyrosine kinase inhibitors therapy and to compare the results with patients receiving IMA. We evaluated the association of these laboratory changes with the risk of future CV events, CV risk dynamics, and use of statins during tyrosine kinase inhibitors administration based on the European Society of Cardiology guidelines.